This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Sep 15, 2025
•
6 min read
🧬 Lila Sciences' "autonomous science" ambitions could net it a $300M+ fundraise, Medicines Discovery Catapult + Crown Bioscience partner on radiopharma development, UK's biopharma industry dealt multiple blows as both AstraZeneca & Eli Lilly reconsider initiatives there, vaccine stocks slide over rumors of Trump admin linking COVID shots to 25 children deaths
Sep 13, 2025
10 min read
A guest post from the Road To Carry Newsletter.
Sep 12, 2025
8 min read
🧬 PE firm GTCR buys former Sanofi generics unit Zentiva from rival PE firm Advent for €4.1B, LB Pharmaceuticals ends(?) biotech IPO drought with $285M raise, Avidity Biosciences prices $600M public offering, Merck & Co.'s positive pneumococcal conjugate vaccine Ph3 data in at-risk children, AbbVie settles with spate of would-be US Rinvoq generic manufacturers, Arrowhead heads Ionis lawsuit alleging Tryngolza rival patent breach, Intercept withdraws Ocaliva from US markets after heightened safety concerns
Sep 11, 2025
9 min read
🧬 Merck & Co. pulls all R&D ops out of UK (and scraps a 1 billion pound sterling R&D centre and future HQ build), Kriya's $320M Series D to fuel gene therapy ambitions, Odyssey nabs $213M Series D for autoimmune ambitions, US non-profit Wellcome Leap lands $100M for "highest need" women's health R&D, Cullinan & Taiho's EGFR exon 20 inhibitor touts promising mid-stage response rates in NSCLC, Novo Nordisk to cut nearly 9,000 roles as part of major restructuring
Sep 10, 2025
🧬 Novartis drops $1.4 billion on Tourmaline Bio buy, Samsung Biologics' $1.3 billion manufacturing deal with a "U.S.-based pharmaceutical company", Eli Lilly launches AI platform for use by small biotechs, Ridge Biotechnologies launches with $25M and drug-linker AI optimization dreams, GLP-1s "highly cost-effective" according to new draft ICER report, Lundbeck heads out of 27 markets as part of major restructuring
Sep 9, 2025
🧬 BioNTech + BMS' bispecific touts positive Ph2 data in small cell lung cancer, NRG Therapeutics raises £50 million going after ALS & Parkinson's, Eli Lilly partners with Remedium Bio on obesity/type 2 diabetes gene therapies, Servier buys Kaerus Bioscience' investigational fragile X syndrome small molecule for up to $450M, FDA rejects Saol Therapeutics' pyruvate dehydrogenase complex deficiency approval bid, FDA debuts consumer GLP-1 "green list" in hopes of stemming illegal GLP-1 API usage
Sep 8, 2025
7 min read
🧬 BioNTech notches Ph3 ADC win in metastatic breast cancer, Delaware-based Braveheart Bio in-licenses Hengrui's late stage selective myosin blocker HRS-1893 for $65M upfront, Summit & Akeso's PD-1xVGEF approval hopes keep ticking due to newly calculated patient survival data, Mineralys Tx closes upsized $287.5M public offering, Japan finesses generic tariff exemption with the US - skirting 15% baseline tariff, WHO put GLP-1's on "Essential Medicine" list but points out high prices, RFK Jr. to (allegedly) link tylenol usage during pregnancy to autism
Sep 6, 2025
We look back on another busy week in Biopharma
Sep 5, 2025
11 min read
🧬 FDA publishes (heavily redacted) CRLs in transparency effort, Atlas Venture's new $400M fund, MindMed's new Ph2 LSD data in generalized anxiety disorder, Judge order Harvard funding reinstatement from Trump admin, an allogeneic CAR-T first for MS in Nebraska (first patient dosed), liver injury risks pushes FDA decision for Agios' Pyrukynd (mitapivat) for thalassaemia back to December, RFK Jr. goes on pharma offensive (again) and spouts mRNA misinformation (again)
Sep 4, 2025
🧬 Treeline Biosciences $200M Series A extension, Galvanize's $100M oversubscribed Series C, Pfizer + Valneva's positive data from third annual Lyme disease booster, Novartis expands RNA collab with Chinese-biotech Argo (up to $5B), big pharma defends pandemic-era Warp Speed initiative as Trump admin scrutiny builds, Kite Pharma ends up to $2.3B collab on off-the-shelf cell therapies with Shoreline Biosciences
Sep 3, 2025
🧬 Amgen's $600M R&D investment in California, CHARM Therapeutics nabs $80M Series B to power menin inhibitor ambitions, Merck & Co.'s oral PCSK9 inhibitor lands another Ph3 win, Novartis brings on Arrowhead's preclinical Parkinson's siRNA for $200M upfront + $2B biobucks, Eli Lilly ditches pair of naperiglipron (oral obesity therapy) Ph2 trials due to "strategic business reasons", Paul Offit ousted from HHS (outspoken RFK Jr. critic and member of FDA's vaccine advisory committee)
Sep 2, 2025
🧬 Novo Nordisk Wegovy bests Eli Lilly Zepbound in real world study on cardiovascular risk, Eli Lilly's DTC push in China with JD Health partnerships, Fosun gains Greater China rights to Accro Bioscience's TYK2/JAK1 inhibitor, Eli Lilly's pirtobrutinib lands UK approval for in relapsed blood cancers, J&J ditches rheumatoid arthritis angle for FcRn blocker nipocalimab after disappointing mid-stage results, University of Michigan sues AstraZeneca regarding FluMist contract renewal dispute
